 |
|
|
| |
Efficacy and Safety of Dolutegravir (DTG) in Hepatitis (HBV or HCV) Co-infected Patients: Results From the Phase 3 Program
|
| |
| |
Reported by Jules Levin
20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia
S Min,1 J Roberts,2 S Almond,2 L Curtis,3 C Stainsby,3 J Lim,4 B Wynne,5 G Nichols1
1-5GlaxoSmithKline, 1ID Medicine Development, Research Triangle Park, NC, USA; 2Statistics, Mississauga, Canada; 3Global Clinical Safety and Pharmacovigilance, Stockley Park, UK; 4Statistics, Stockley Park, UK; 5ID Medicine Development, Upper Providence, PA, USA
|
| |
|
|
|
|
|
